Tenax Therapeutics Reports Third Quarter 2020 Results and Provides Business Update
Nov 16, 2020
Tenax Therapeutics Announces Presentation of 24-Hour HELP Study Results at the American Heart Association Scientific Sessions 2020
Nov 10, 2020
Tenax Therapeutics to Host Virtual R&D Webinar with Scientific Experts Highlighting HELP Study Results
Nov 6, 2020
Tenax Therapeutics Gains North American Rights to Oral Levosimendan through Expanded License Agreement with Orion Corporation
Oct 15, 2020
Tenax Therapeutics Announces Late-Breaking Clinical Trial Presentation of Phase 2 HELP Study at Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting
Oct 2, 2020
Tenax Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference
Sep 1, 2020
Tenax Announces Late-Breaking Results from the HELP Study Accepted for Presentation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting
Aug 31, 2020
Tenax Therapeutics Reports Second Quarter 2020 Results and Provides Business Update
Aug 17, 2020
Tenax Therapeutics Expands Board of Directors with the Appointment of Two New Directors, Steven Boyd and Keith Maher, MD
Jul 20, 2020
Tenax Therapeutics Announces $8.0 Million Registered Direct and PIPE Offerings Priced At-the-Market Under Nasdaq Rules
Jul 6, 2020